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It is speculated that a virus-encoded superantigen is involved in the pathogenesis of human and simian immunodeficiency
virus infections and that the accessory protein Nef might be that superantigen. We are able to show, using a murine
superantigen screening system, that Nef does not display features characteristic of a superantigen. Upon transfection into
MHC class II expressing antigen-presenting cells, it is expressed, but fails to induce Vb-specific expansion of peripheral T
lymphocytes, which is a characteristic feature of superantigens in mixed lymphocyte culture. Therefore, we cannot support
the hypothesis that Nef is a superantigen. The observations in favor of that hypothesis must be explained by other
mechanisms. © 2001 Academic Press
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Several observations may suggest the existence of a
superantigen in human immunodeficiency virus (HIV)
and simian immunodeficiency virus (SIV). Superantigens
are proteins that cause a MHC class II-mediated activa-
tion of T lymphocytes expressing a certain allele of the T
cell receptor (TCR) Vb chain. In vivo, this activation typ-
cally results in a polyclonal expansion of that Vb subset,
ollowed by a diminution of the population and anergy to
enewed stimulation (White et al., 1989).
In support of the superantigen hypothesis are reports
f differences in the Vb repertoire of HIV-infected per-
ons in comparison with noninfected individuals (McCoy
t al., 1995; Imberti et al., 1991) and even in pairs of
onocygotic twins, one of them HIV infected, the other
ot (Rebai et al., 1994). Additionally, anergy of T lympho-
ytes of HIV-infected humans to stimulation with bacte-
ial erythrogenic toxin A from Streptococcus pyogenes
nd staphylococcal enterotoxin E from Staphylococcus
ureus (Dadaglio et al., 1994) and viral superantigens
rabies virus nucleocapsid (Scott-Algara et al., 1994)) was
escribed. An HIV superantigen would also explain the
poptosis of uninfected bystander cells (Finkel et al.,
995), which might be one mechanism for the loss of
D41 cells during HIV infection.
A polyclonal expansion of Vb7 and Vb14 cells was
bserved in macaques infected with simian immunode-
iciency virus SIVsmmPbj14 (Chen et al., 1994), a SIV mu-
tant that causes a rapidly progressive disease with as-
1 To whom correspondence and reprint requests should be ad-
ressed. Fax: 1149/89/4140-4868. E-mail: Thomas.Miethke@lrz.tu-
uenchen.de.
329pects of toxic shock and massive lymphoproliferation
(Sasseville et al., 1996). Interestingly, the acutely patho-
genic phenotype was correlated with a mutation in the
nef gene, and the characteristic in vitro phenotype of the
mutation, an activation of lymphocytes in resting periph-
eral blood mononuclear cell (PBMC) cultures, was de-
pendent on the presence of antigen-presenting cells
(APCs) (Du et al., 1995).
Another hint of Nef being a superantigen was the
observation that Nef of HIV-1BRU induced proliferation of
uman T cells linked by Vb-specific antibodies to a
microtiter plate differently for different Vb subsets (Torres
et al., 1996; Tanabe et al., 1997). However, this approach
was problematic because a binding of antibodies to
parts of the TCR before stimulation may have biased the
results. The standard method for evaluating Vb shifts,
low cytometry analysis, failed to show conclusive re-
ults, as stated by Tanabe et al. (1997).
On the other hand, HIV-1 infection of SCID-hu mice did
not alter the relative Vb distribution of human thymo-
cytes, in contrast to the injection of the bacterial super-
antigen staphylococcal enterotoxin B (Komanduri et al.,
1997), arguing against the existence of an HIV-1 encoded
superantigen. Similar findings were published by Boldt-
Houle (1997).
The search for superantigen-induced alterations in the
Vb distribution of human T cells is quite difficult. First of
ll, there are 47 different Vb segments to analyze (Arden
t al., 1995a). This indicates that the Vb populations are
relatively small (between 0.1 and 7% of all T cells), which
complicates the detection of perturbations in Vb distri-
bution relative to the methodically caused background
variability. The reproducibility of experiments is further
0042-6822/01 $35.00
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330 LAPATSCHEK ET AL.impaired by the high level of diversity in the Vb repertoire
etween individuals.
On the other hand, in mice there exist only 20 different
b segments with Vb population sizes up to 33%, making
the mouse system much more sensitive for superantigen
detection (Arden et al., 1995b). In addition, Vb distribution
is perfectly reproducible between individuals belonging
to the same inbred strain. Although there are differences
between the human and the murine immune systems,
the principles of superantigen recognition, i.e., MHC
class II-dependent presentation and Vb-specific activa-
tion of T cells, are the same (Marrack and Kappler, 1990).
Furthermore, the Vb chains of the TCR involved in the
ecognition of the different superantigens are conserved
etween humans and mice (Herman et al., 1991; La-
recque et al., 1993). Thus, of all superantigens known
o far, there is no one whose action is confined to only
ne of the two species. Therefore, we applied our well-
stablished murine system for superantigen detection
Wintersperger et al., 1994; Lapatschek et al., 2000),
which also circumvents the problem of alloreactivity en-
countered in human-based test systems or of xenoreac-
tivity observed in human/murine-based test systems, to
the evaluation of a possible superantigen function of the
nef genes of human and simian immunodeficiency vi-
ruses.
RESULTS
For the superantigen detection assay A20 cells were
transiently transfected with expression vectors contain-
ing the genes of the putative superantigens and coculti-
vated with murine T-cells. The latter were then analyzed
for shifts in the Vb distribution and for proliferation, to
detect possible superantigen-induced Vb-specific cell
FIG. 1. Transfection efficiency of A20 cells. A20 cells were trans-
ected with the EGFP-encoding plasmid pEGFP-N1 and after 24 h the
ells were analyzed by FACS for the expression of EGFP. The bottom
raph depicts the viable EGFP transfected cells; the top graph depicts
ells transfected with an empty vector.ctivation. Nef genes of SIV (PBJ, MAC) and HIV-1 (BRU,
1L, G5H, PA1, R71, TH, YU2) were examined in this
l
gystem. The plasmid pSG5-K, which contains the HIV-1
U2 nef gene in reverse orientation, served as a negative
ontrol. As positive controls a plasmid containing the
stablished superantigen from mouse mammary tumor
irus 2 (pMMTV2Sag) and the bacterial superantigen
taphylococcal enterotoxin B (SEB) were used.
ranscription and protein expression of Nef in A20
ells
First, we verified that the plasmids were transcribed in
he transfected cells. A plasmid encoding the enhanced
reen fluorescent protein (EGFP) was used to measure
he transfection efficiency of A20 cells. As shown in Fig.
approximately 50% of all living cells were transfected.
ach of the subsequent nef transfection experiments
as paralleled by an EGFP expression control. The
ransfection efficiency remained stable throughout all
xperiments.
Then, we checked the cells for expression of the
ransfected nef genes. We performed Western blots us-
ng a rabbit antiserum generated against the Nef protein
rom HIV-1BRU (Fig. 2). This 27-kDa protein served as a
ositive control and, as indicated in lane 1 by the arrow,
as recognized by the antiserum. A corresponding band
s visible in the lysates of the cells transfected with BRU,
1L, PA1, and R71, in contrast to cells transfected with
he negative control vector pSG5-K. The Nef band of G5H
ad a higher molecular weight, which is consistent with
he in-frame insertion of 10 additional amino acids near
he N-terminal end of the protein. Another blot confirmed
he presence of the Nef protein in TH transfectants (data
ot shown). The YU2 expression product was not de-
ected by our antibody (data not shown), probably be-
ause stretches of different amino acids altered the
ntigenic sites too much. The MAC and PBJ transfectants
FIG. 2. Expression of the Nef protein in transfected A20 cells. A20
cells were transfected with the indicated plasmids. Twenty-four hours
later cells were lysed with NP-40 and the cell lysate was analyzed by
Western blot using the rabbit anti-Nef antiserum. The first lane contains
the 27-kDa band (arrow) from the purified Nef protein from HIV-1BRU; the
ells transfected with BRU, G1L, PA1, and R71 show the same band, in
ontrast to the pSG5-K transfectant. The Nef protein of G5H is slightlyarger because of an in-frame insertion of 30 bp near the 59 end of the
ene.
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331EVALUATION OF Nef AS SUPERANTIGENlikewise showed no Nef band in the Western blot (data
not shown), as we expected, because of the high degree
of sequence difference between HIV-1 and SIV. Never-
theless, we were able to show by RT-PCR (Fig. 3) that PBJ
and YU2 are efficiently transcribed into mRNA. As all
conditions were the same as for the other transfectants,
we assumed that the corresponding proteins of PBJ and
YU2 were comparably expressed.
MHC class II expression on nef-transfected cells
Nef is known to down-regulate the surface expression
of CD4 (Aiken et al., 1994) and MHC class I (Collins et al.,
1998). A similar effect on MHC class II is not described.
Nevertheless we approached this crucial question, since
in order to activate T cells, bacterial and retroviral super-
antigens need to be presented by MHC class II express-
ing antigen-presenting cells (Acha-Orbea, 1992; Marrack
and Kappler, 1990; Bressler et al., 1993). We analyzed the
expression of MHC class II molecules on the cell surface
24 h after transfection of the A20 cells. Figure 4 shows
that the expression level of MHC class II molecules is
not influenced by Nef, when compared with nontrans-
fected as well as with pSG5-K- and MMTV2Sag-trans-
fected cells. Thus, the same amount of MHC II molecules
would be available for a putative Nef superantigen as for
MMTV2Sag.
Test of superantigen function using the murine test
system
Syngenic murine peripheral T cells were stimulated
with transfected A20 cells for 5 days and subsequently
FIG. 3. Transcription of mRNA for PBJ and YU2 in transfected A20
cells. A20 cells transfected with the PBJ and YU2 expression vectors
were tested by RT-PCR for the presence of messenger RNA encoding
the transfected gene products. As shown in lanes 2 (PBJ) and 3 (YU2),
specific bands were found. These bands were of the same size as the
PCR products amplified directly from the plasmids (lanes 6 (PBJ, plas-
mid) and 7 (YU2, plasmid)). If the reverse transcriptase was omitted in
an otherwise identical assay, no amplification products were found
(lanes 4 (PBJ, 2RT) and 5 (YU2, 2RT)). This indicates that the bands in
lanes 2 and 3 are truly amplified from mRNA and not from the trans-
fected plasmids.analyzed by FACS for a Vb-specific outgrowth of T cells.
b3, Vb5, Vb11, and Vb12 are known to be deleted inBALB/c mice and were thus not examined. The Vb2 and
Vb17 subsets were too small to give a distinct, reproduc-
ble population in the FACS scan (data not shown). The
esults for the Vb4, Vb6, Vb7, and Vb8 subsets are
epicted in Fig. 5a and the results for the Vb9, Vb10,
FIG. 4. Expression of MHC class II molecules on A20 cells is not
influenced by Nef. Native and transfected A20 cells were analyzed for
the expression of MHC class II molecules 24 h after electroporation.
Cells were stained with an FITC-labeled anti-MHC class II antibody and
the expression level of MHC class II was recorded with the cytometer.
Solid lines depict the isotype controls; shaded areas represent the
expression of class II MHC.
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332 LAPATSCHEK ET AL.Vb13, and Vb14 subsets are shown in Fig. 5b. As already
entioned the system was controlled with two estab-
ished superantigens: first, with the exogenous bacterial
uperantigen, SEB, which stimulates all murine Vb81 T
cells (Marrack and Kappler, 1990), and second and more
importantly, with the superantigen-encoding ORF of
MMTV2, which stimulates all murine Vb141 T cells. As
expected, SEB expanded all Vb81 T cells, which resulted
in a relative reduction of the other T cell subsets tested.
The MMTV2-encoded superantigen stimulated all Vb141
cells and again the relative numbers of the other T cell
subsets were reduced. In contrast, neither the two most
interesting candidates for a superantigen, PBJ and BRU,
nor the other investigated SIV and HIV Nefs, MAC, G1L,
G5H, PA1, R71, TH, and YU2, induced an increase or a
FIG. 5. Different nef constructs do not change the relative distributio
the indicated plasmids (20 mg DNA/1 3 107 cells). After 24 h the cells w
t a density of 5 3 106 cells/well. Murine peripheral lymph node cells
f 10 U/ml IL-2 the cells were harvested. After double staining with mA
TCR and with a mAb specific for the CD3e protein the individual T cel
(p) Vb81 T cells; (b) (n ) Vb91, (h) Vb101, (o) Vb131, (p) Vb141 T cells
ndicate standard error. Nil are lymph node cells without addition of tra
EB instead of stimulation with transfected cells. pMMTV2Sag is the p
ositive control, and pSG5-K is the negative control vector.decrease of any tested Vb population compared to the
egative control pSG5-K or to native T cells (nil).
t
pVb1, Vb15, and Vb16 T cells were not assessed in the
low cytometry analysis because of the lack of commer-
ially available antibodies specific for these Vb seg-
ents. Therefore, we also measured the induced prolif-
ration of the peripheral T cells as a parameter for
uperantigen response. As depicted in Fig. 6 only the
ontrol superantigens, SEB and the ORF encoded by
MTV2, stimulated T cells to proliferate significantly.
he nef-encoding plasmids induced proliferation of the T
ells at the same level as the expression vector pSG5-K
acking a coding sequence.
DISCUSSION
The most fatal consequence of an infection with HIV is
1
subsets in murine peripheral T cells. A20 cells were transfected with
ted with mitomycin C (80 mg/ml) and used as antigen-presenting cells
dded (2.5 3 106 cells/well) and after 5 days of culture in the presence
cific for the Vb4, Vb6, Vb7, Vb8, Vb9, Vb10, Vb13, or Vb14 chain of the
pulations were quantified by FACS ((a) (n ) Vb41, (h) Vb61, (o) Vb71,
bar represents the mean of four independent experiments; error bars
d cells or any other stimuli; SEB stands for cells treated with 1 mg/ml
with the superantigen from mouse mammary tumor virus 2, serving asn of Vb
ere trea
were a
bs spe
l subpo
). Each
nsfectehe loss of CD4 cells, which finally leads to AIDS. One
ossible explanation for this loss, which is not confined
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333EVALUATION OF Nef AS SUPERANTIGENto the infected cells, but also involves uninfected by-
stander cells (Finkel et al., 1995), would be the deletion
y an HIV-associated superantigen. The most interesting
andidate for such a superantigen is nef, an accessory
gene that enhances HIV replication in infected cells
(Miller et al., 1994; Kawano et al., 1997). Nef-transgenic
mice show a depletion of CD41 cells (Lindemann et al.,
994; Skowronski et al., 1993), in addition to the down-
egulation of CD4 and MHC class I. An intact Nef is
mportant for pathogenicity of SIV (Kestler et al., 1991),
nd nef mutations have been found in HIV-infected long-
erm survivors (Deacon et al., 1995). Nef bound to the
ost cell membrane is incorporated into the virion during
udding (Bukovsky et al., 1997) and MHC class II mole-
cules captured in the same way are shown to be able to
present superantigens (Rossio et al., 1995). If Nef was a
superantigen, HIV could thus activate lymphocytes with-
out the help of APCs. Nevertheless, the macrophage-
tropic strains of HIV are considered to be dominant
during early infection, so that HIV is always present in
infected APCs such as macrophages. In vitro, Nef of
HIV-1BRU in combination with APCs induces proliferation
f specific Vb subsets of human T cells linked by Vb-
specific antibodies to a microtiter plate (Torres et al.,
1996; Tanabe et al., 1997). As mentioned above, these
results may be biased by the binding of antibodies to the
TCR before stimulation. This bias may account for the
difference in the findings shown here that seven HIV-1
Nefs including HIV-1BRU Nef do not alter the Vb distribu-
FIG. 6. Proliferation of murine T cells stimulated by different nef-
encoding plasmids. The experiment was performed as in Fig. 5. After a
culture period of 4 days the cells were pulsed for 8 h with [3H]thymidine
(37 kBq) and incorporation of [3H]thymidine was determined. Each bar
epresents the mean of quadruplicates; error bars indicate standard
rror. The experiment was repeated twice with comparable results.ion of peripheral lymphocytes. On the other hand, our
ystem would not detect a superantigen effect, if Nef
a
ainds only to human and not to murine MHC class II and
CR. We consider this possibility as rather improbable,
oncerning the fact that human and murine Vb chains
re so conserved that all superantigens known so far
xert their effects on T cells of both species, as men-
ioned above. An alternative explanation would be that
ef exhibits its superantigenic site only when present in
soluble form, as mentioned by Johnson et al. (1996).
hough possible, this mechanism is not likely to contrib-
te to a pathogenicity in vivo, considering the tight mem-
rane association of functional Nef. Thus we think that
ur system of presenting the putative superantigen by
ransfection into an APC is much nearer to an actual
irus infection. Nevertheless, we addressed the effect of
oluble Nef on the Vb repertoire of peripheral T cells in
n initial experiment by injecting Nef into the footpad of
BALB/c mouse. The subsequent analysis of the Vb
distribution in the popliteal lymph node showed no dif-
ference from the untreated control mouse (data not
shown). We also cannot rule out the possibility that the
putative superantigen activates only Vb3, Vb5, Vb11, or
Vb12 T cells, which are deleted in BALB/c mice. This
ssue can be solved only by using other strains of mice
ith different Vb-specific deletions of T cells. However,
he necessary antigen-presenting cells with properties
imilar to those of A20 cells, i.e., good transfection effi-
iency and MHC class II expression, were not available
nd using A20 cells with other strains of mice would
nduce an allogenic stimulation of T cells. If Nef is not a
uperantigen, the observations supporting the superan-
igen hypothesis may find other explanations. The deple-
ion of CD41 cells in nef-transgenic mice (Lindemann et
al., 1994; Skowronski et al., 1993), as well as the apopto-
sis of uninfected bystander cells (Finkel et al., 1995), may
be explained by a direct apoptotic property of Nef shown
to exist at least in vitro (Okada et al., 1997). Nef is
reported to have an intrinsic activity in the TCR signaling
cascade (see below (Luo and Peterlin, 1997)), but can
also inhibit the signaling in response to external stimuli
(Greenway et al., 1996) and may in this way contribute to
the anergy of T lymphocytes of HIV-infected humans to
stimulation with bacterial (Dadaglio et al., 1994) and viral
superantigens (Scott-Algara et al., 1994). The differences
in the Vb repertoire of HIV-infected persons in compari-
on with noninfected individuals (McCoy et al., 1995;
mberti et al., 1991; Rebai et al., 1994) may be an oligo-
lonal artifact as described by Pantaleo et al. (1994) (see
elow) or may be due to a superantigen of another
nfectious agent. For example, a preferential replication
f HIV in certain Vb T cell subsets turned out to be a
uperantigenic effect of cytomegalovirus (Laurence et
l., 1992; Posnett et al., 1995; Dobrescu et al., 1995a,b).
If we reckon that in general HIV Nef is not a superan-
igen, still the most convincing data for the existence oflentiviral superantigen come from the distinct SIV vari-
nt SIVsmmPbj14. This variant causes a rapidly progres-
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334 LAPATSCHEK ET AL.sive toxic shock-like disease, induces previously un-
stimulated T cells to proliferate considerably, and cre-
ates a polyclonal expansion of Vb7 and Vb14 cells in
nfected macaques (Chen et al., 1994). As mentioned
before, the acutely pathogenic phenotype is correlated
with a mutation in the nef gene, shown by the following
experiment (Du et al., 1995): A molecular clone of SIV-
mac239 was generated with four bases in the nef gene
substituted with the corresponding bases of SIVsmmPbj14,
eading to a mutation of the amino acids 17R18Q to 17Y18E.
his clone, named SIVmac239YE, showed the same acutely
athogenic phenotype as SIVsmmPbj14 upon infection of
macaques. In vitro, the mutated virus exhibited some
distinct features different from the wild-type virus. It is
able to replicate in unstimulated PBMCs and can induce
proliferation of resting PBMCs depending on the pres-
ence of macrophages. The reverse experiment, a substi-
tution of 17Y18E of the Nef of SIVsmmPbj14 by
17R18Q, led to
an impairment of the virus to replicate in macrophages
and to induce proliferation of PBMCs (Saucier et al.,
1998). The ability to replicate in unstimulated PBMCs
remained unchanged. Thus, the feature characteristic of
a superantigen, the induction of T cell expansion in the
presence of MHC II-bearing cells, is clearly confined to
the YE motif. This made the nef gene the most plausible
candidate for a putative superantigen in SIVsmmPbj14.
evertheless, as we show here, Nef of SIVsmmPbj14
causes no Vb-specific proliferation of T cells, compared
ith the Nef of SIVmac or the negative control and thus
eems not to be a superantigen. So the induction of T
ell proliferation by the Nef of SIVsmmPbj14 is probably
due to another mechanism. The YE mutation inserts an
additional SH2-binding domain (Du et al., 1995). This
immunoreceptor tyrosine-based activation motif (ITAM)
is shown to be functional and, when phosphorylated by
the Src family kinase Lck, is able to mimic a TCR signal
by binding to the tyrosine kinase ZAP-70, which could
contribute to T cell proliferation (Luo and Peterlin, 1997).
The necessary presence of macrophages could reflect
the need for a costimulatory signal from APCs. This
signal might be provided by the activation of macro-
phages. Interestingly, it was shown that murine macro-
phages are directly activated by a naked short DNA
sequence of the nefs of SIVsmmPbj14 and SIVmac239YE, but
not of the corresponding sequence of SIVmac239
(Lapatschek et al., 1998). The observed expansion of Vb7
nd Vb14 cells in SIVsmmPbj14-infected animals may be,
though polyclonal, only an exaggeration of the oligo-
clonal Vb expansion observed in animals infected with
ther SIVs (Chen et al., 1995), or HIV-infected humans
Pantaleo et al., 1994), instead of being a superantigen
effect. It was suggested that this oligoclonal Vb expan-
ion is part of the cytotoxic T lymphocyte (CTL) response
o an early infection, because of its correlation with a
ertain MHC class I allele and the emergence of SIV-
pecific CD81 CTLs (Chen et al., 1995).In conclusion, we could show that Nef is not a super-
antigen and that the variety of other effects it has on T
lymphocytes is sufficient to render it a major virulence
factor during HIV infection.
MATERIALS AND METHODS
Reagents and antibodies
The biotinylated anti-murine Vb6 (clone RR4-7), Vb8
(clone F23.1), and Vb14 (clone 14-2) monoclonal antibod-
es (mAbs), the phycoerythrin (PE)-labeled anti-murine
b2 (clone B20.6), Vb7 (clone TR310), Vb9 (clone MR10-
2), Vb10 (clone B21.5), Vb13 (clone MR12-3), Vb17 (clone
KJ23) mAbs, the FITC-labeled anti-murine CD3e mAb
(clone 145-2C11), and the FITC-labeled anti-murine I-Ad/
I-Ed mAb (clone 2G9) together with the corresponding
isotype control (clone R35-95) were purchased from
Pharmingen (San Diego, CA). The hybridoma KT4 pro-
ducing an anti-murine Vb4 mAb was kindly donated by
r. H. Hengartner (Zu¨rich, Switzerland). The antibody
as purified and biotinylated according to standard pro-
ocols. PE-conjugated streptavidin was purchased from
ackson ImmunoResearch (West Grove, PA), and SEB
BT202) was from Toxin Technology (Sarasota, FL). The
urified Nef protein from HIVBRU and the polyclonal rabbit
nti-Nef antiserum were kindly provided by Dr. B.
ohleisen (Neuherberg, Germany).
ell culture
The murine B cell lymphoma A20 cell line (Kim et al.,
979) was cultured in Click’s RPMI (Seromed Biochrom,
erlin, Germany) with 10% fetal calf serum (FCS, Bio-
hittaker, Verviers, Belgium), 2 mM glutamine (Seromed
iochrom), 100 U/ml penicillin and 100 mg/ml streptomy-
cin (Seromed Biochrom), 50 mM 2-mercaptoethanol
Gibco BRL, Paisley, Scotland), 1 mg/ml indomethacine
Sigma, Deisenhofen, Germany).
Murine lymphocytes were freshly prepared from the
esenterial lymph nodes of BALB/c mice (Harlan,
orchen, Germany) by teasing through a mesh metal
ieve. Over 85% of the viable cells were CD31 T cells, as
assessed by flow cytometry.
Plasmids
pEGFP-N1 was kindly donated by Dr. H. Ha¨cker (Mu-
nich, Germany), and pMMTV2Sag was a gift from Dr. W.
Gu¨nzburg (Vienna, Austria). The eukaryotic expression
vector pSG5 from Stratagene (La Jolla, CA) was used to
express the coding sequences of different nef genes
under the transcriptional control of the SV 40 early pro-
moter. The following nef gene fragments were prepared
by restriction digestion or PCR and cloned into the mul-
tiple cloning site (EcoRI, BamHI, or BglII) of pSG5: PBJ
contains the nef gene of the highly pathogenic
SIVsmmPbj14 strain, MAC contains the nef of SIVmac251,
c
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335EVALUATION OF Nef AS SUPERANTIGENand pSG5-K is a control vector with HIV-1 YU2 nef in
reverse orientation to make Nef synthesis impossible.
BRU is derived from HIV-1BRU (synonymous to the HIV-1IIIB
isolate LAI), TH is from HIV-1IIIB passaged in astrocytoma
ells, YU2 is from a brain-specific molecular clone of
IV-1YU2, G1L is from a primary HIV-1 isolate from cere-
rospinal fluid, G5H is from a primary HIV-1 isolate from
rain, and PA1 and R71 are from mutant nef genes of
IV-1NL4-3.
ransfection
Twenty-four hours after being passaged, 1 3 107 A20
ells in a volume of 400 ml RPMI/10% FCS with 20 mg of
plasmid DNA were electroporated in a 0.4-cm cuvette at
960 mF and 280 V using a Bio-Rad Gene Pulser (Bio-Rad,
Hercules, CA). Transfection efficiency was controlled
with the pEGFP-N1 vector by flow cytometry 24 h post-
transfection.
Detection of mRNA by reverse transcription and PCR
Transfected cells (6 3 106 A20 cells, 20 mg plasmid
DNA) were cultured overnight (37°C). After centrifugation
(1200 rpm for 5 min) the pellet was lysed with 600 ml RLT
buffer (Qiagen, Hilden, Germany). RNA was extracted
using the RNeasy kit (Catalog No. 74103) from Qiagen.
The amount of RNA was quantified photometrically (260
nm). Thereafter, contaminating DNA was digested with
DNase (20 U/2 mg RNA, 10 min at 37°C, Roche Diagnos-
tics GmbH, Mannheim, Germany) and cDNA was syn-
thesized using 1 ml oligo(dT) (10 mM, Gibco Life Tech-
ologies Inc., Rockville, MD), 1 ml hexamer random
primer (10 mM, Gibco), 4 ml of 53 transcription buffer
Gibco), 2 ml of 0.1 M DTT (Gibco), 2 ml dNTP (200 mM,
oche), 0.5 ml Rnasin (Promega, Madison, WI), and 1 ml
Superscript II Plus (Gibco). The reaction mixture was
incubated for 60 min at 37°C and subsequently heated to
95°C for 5 min.
Two microliters of the generated cDNA was used for
PCR amplification to detect the transcribed nef mRNAs of
SIVsmmPbj14 or HIV-1YU2 using the primers 59 Pbj (59-
ATGGGTGGCGTTACCTCCAAGAAGC-39) and 39 Pbj (59-
TTAGCTTGTTTTCTTCTTGTCAGCCATT-39) or 59 YU2 (59-
ATGGGTGGCAAGTGGTCAAAAAGTAG-39) and 39 YU2
59-TCAGCAGTTCTTGAAGTACTCCGGATG-39), respec-
ively. The PCR mixture consisted of 10 ml dNTP (1 mM,
Roche), 1.5 ml of each of the primers (50 mM, TIB Mol-
biol), 29 ml H2O, 1 ml Pfu Turbo (Invitrogen, Carlsbad, CA),
nd 5 ml of 103 buffer (Invitrogen). The cycle conditions
ere 94°C for 30 s for denaturation, 68°C for 60 s for
nnealing, and 72°C for 120 s for elongation. The PCR
as run for 35 cycles. The PCR products were visualized
ith an ethidium bromide stained 1% agarose gel.estern blot
Transfected cells (5 3 106 A20 cells, 20 mg plasmid
DNA) were cultured overnight (37°C) and subsequently
lysed in NP-40 (1% v/v). Cell lysates were separated by
sodium dodecyl sulfate–polyacrylamide gel electro-
phoresis (SDS–PAGE, 12.5%) using Laemmli sample
buffer (15.1 g/L Tris, 9.4 g/L glycine, 0.5% SDS). After
being transferred onto nitrocellulose by semidry elec-
troblotting for 2 h (250 mA), the filters were blocked (5%
milk powder in TBST, 1 h at 37°C and 1 h at room
temperature) and incubated with the rabbit anti-Nef an-
tiserum (diluted 1:2000, overnight at 4°C). After three
wash steps with 13 TBST (2.4 g/L Tris, 8 g/L NaCl, 0.1%
Tween, pH 7.6), anti-rabbit serum coupled with peroxi-
dase was added (diluted 1:5000, 1 h at room tempera-
ture, Dianova, Hamburg, Germany). The blot was washed
again three times with 13 TBST and visualized by using
the ECL reagent (NEN Life Science Products, Boston,
MA) as described by the manufacturer.
Mixed lymphocyte culture
Twenty-four hours after transfection, A20 cells were
growth-arrested by a 1-h incubation with 80 ng/ml mito-
mycin C and after three washings subsequently cocul-
tured at a stimulator:responder ratio of 2:1 with BALB/c
lymphocytes in RPMI/10% FCS with 10 U/ml interleukin 2
for a culture period of 4 to 5 days.
FACS analysis
After MLC, viable T lymphocytes were retrieved from
coculture by gradient centrifugation with Ficoll at a den-
sity of 1.090. The cells were then stained with the anti-Vb
antibodies (diluted 1:100) mentioned above and counter-
stained with anti-CD3 (diluted 1:100). In case of biotinyl-
ated antibodies, a second staining step with strepta-
vidin–PE (diluted 1:100) was added. The FACS analysis
was performed with a Facscalibur cytometer (Becton
Dickinson, Franklin Lakes, NJ).
Proliferation assay
The proliferative response of the T cells was mea-
sured on day 4 by pulsing microcultures with 37 kBq
[3H]thymidine (NEN, Zaventem, Belgium) for 8 h. There-
after cultures were harvested on glass fiber filters and
[3H]thymidine incorporation was determined by direct
eta counting (Matrix 96, Packard Instrument Co., Meri-
en, CT).
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